In a filing, Predictive Oncology Inc. revealed its Director HANDLEY DANIEL E acquired Company’s shares for reported $2460.0 on Dec 15. In the deal valued at $0.41 per share,6,000 shares were bought. As a result of this transaction, HANDLEY DANIEL E now holds 120,513 shares worth roughly $ 37359.03.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Then, MYERS ROBERT L bought 8,795 shares, generating $5,001 in total proceeds. Upon buying the shares at $0.57, the CHIEF FINANCIAL OFFICER now owns 71,265 shares.
Before that, Vennare Raymond F bought 5,000 shares. Predictive Oncology Inc. shares valued at $2,583 were divested by the Director at a price of $0.52 per share. As a result of the transaction, Vennare Raymond F now holds 83,730 shares, worth roughly $25956.3.
Price Performance Review of POAI
On Friday, Predictive Oncology Inc. [NASDAQ:POAI] saw its stock fall -8.53% to $0.31. On the same session, the stock had its day’s lowest price of $0.301, but rose to a high of $0.37. Over the last five days, the stock has lost -28.55%. Predictive Oncology Inc. shares have risen nearly 1.04% since the year began. Nevertheless, the stocks have fallen -66.69% over the past one year. While a 52-week high of $1.10 was reached on 02/06/23, a 52-week low of $0.21 was recorded on 01/03/23. SMA at 50 days reached $0.4334, while 200 days put it at $0.3911. A total of 0.83 million shares were traded, compared to the trading of 1.44 million shares in the previous session.
Levels Of Support And Resistance For POAI Stock
The 24-hour chart illustrates a support level at 0.2839, which if violated will result in even more drops to 0.2579. On the upside, there is a resistance level at 0.3529. A further resistance level may holdings at 0.3959. The Relative Strength Index (RSI) on the 14-day chart is 32.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0581, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.13%. Stochastics %K at 13.96% indicates the stock is a buying.
How much short interest is there in Predictive Oncology Inc.?
A steep rise in short interest was recorded in Predictive Oncology Inc. stocks on Jan 12, 2023, growing by 20750.0 shares to a total of 0.25 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 0.23 million shares. There was a rise of 8.16%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 0.33% of the overall stock float, the days-to-cover ratio (short ratio) rose to 1.08.
Predictive Oncology Inc. [POAI] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 2,099,534 shares, or roughly 2.67% of the outstanding POAI shares. In other words, the investor’s shares have risen by 1,376 from its previous 13-F filing of 2098158.0. Additionally, Geode Capital Management LLC decreased -0.21% of its stake after which the total value it holdings stand at $275,208, while Renaissance Technologies LLC added 26.95% of its stake to hold $0.13 million in the firm. At present, T. Rowe Price International Ltd. is holding 227,900 shares valued at $97085.0. Carnegie Mellon University owned 207,144 shares of the company at the time of its most recent 13F filing, worth $88243.0.
According to FactSet, Predictive Oncology Inc.’s share price will average $5.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 1370.59 percent from its previous closing price of $0.34. Analysts expect Predictive Oncology Inc. stock to reach the higher price of $5.00, while the lowest price estimate is $5.00. However, 1 analyst have rated POAI stock as a Buy in their predictions for 2023.